-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
The PRAC starts a new review of Xeljanz and recommends the withdrawal of the marketing authorisations for fenspiride medicines. A monthly statistical overview of the PRAC activity is available now on our website.
-
Working together for safe medicines in the EU
Working together for safe medicines in the EU
-
Working together for safe medicines in the EU
Working together for safe medicines in the EU
EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines safe and effective.
-
Questions and answers on EU actions to prevent shortages due to Brexit
Questions and answers on EU actions to prevent shortages due to Brexit
-
Questions and answers on EU actions to prevent shortages due to Brexit
Questions and answers on EU actions to prevent shortages due to Brexit
EMA has published a questions-and-answers document for patients, healthcare professionals, farmers and pet owners, and the general public on the preparatory work that EU authorities are doing to prevent medicines shortages due to Brexit.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
